Investment Legend Paul Mampilly Believes That Precision Medicine Is One of the Best Investment Opportunities Available Today

Paul Mampilly is an American investor who started his career on Wall Street back in 1991 as an assistant portfolio manager at the firm Bankers Trust. Quickly advancing in his professional career, he attained positions at Deutsche Bank and ING managing multimillion-dollar accounts. In 2006 Paul was recruited by Kinetics Asset Management to manage the firm’s hedge fund. His insightful leadership saw the firms assets grow to $25 billion. Follow Paul on Medium. This led the financial publication Barron’s to name Kinetic Asset Management as one of the best hedge funds in the world. This brought Paul to the attention of The Templeton Foundation who invited him to take part in their prestigious investment competition. Given the opportunity to invest $50 million, Paul made a 76% return in only a two-year period. Even more impressive, this accomplishment was achieved during the economic crisis of 2008-2009. This success gave Paul victory in the competition and brought him into the limelight with appearances on Fox Business News, Bloomberg TV and CNBC. Visit to know more about Paul Mampilly.

Today, Paul Mampilly is a senior editor at Banyan Hill Publishing where he is able to focus on his true passion – helping average investors make money on their investments. Upon joining Banyan Hill, Paul started the newsletter Profits Unlimited which focusses on that exact passion. To date, Profits Unlimited currently has 60,000 subscribers. In this monthly publication, Paul Mampilly recommends new stocks to his subscribers. As an addition to this amazing service, he also updates his subscribers weekly on one or two stocks in the model portfolio and tracks how the investments are currently faring. Recently, Paul Mampilly has encouraged his Profits Unlimited readers to invest in precision medicine. He believes that this industry is due to explode financially and it will happen sooner than expected. Precision medicine is medical care that is designed to optimize efficiency or therapeutic benefit for groups of patients by using genetic or molecular profiling. Investors take Paul Mampilly’s investment advice seriously because of his track record. He has been retired for 20 years, being able to do so at the age of 45 because of his smart investments. His investments in the early days of Amazon and Netflix and his ability to see that these enterprises were future success stories are a testament to his insightful and shrewd mind for investment. For this reason, taking his advice in regard to the future of precision medicine is a really good idea.